Almirall, Happify partner on digital tool for psoriasis mental health -

"It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body can have skin lesions. Now, drugmaker Almirall and digital health firm Happify are working on a tool to support mental health in these patients.
Almirall is a specialist in psoriasis therapies with drugs like Skilarence (dimethyl fumarate) and Ilumetri (tildrakizumab), while Happify’s app is designed to drive away negative thoughts through the use of games, mindfulness exercises and other activities such as carrying out acts of kindness.
The two partners say they will develop a specific version of the app for people with psoriasis – called Claro – that will use “cognitive behavioural therapy, positive psychology and mindfulness” to improve the wellbeing of psoriasis patients.
A meta-analysis of clinical studies published in 2014 estimates that 20%-30% of patients with moderate to severe psoriasis suffer from mental health issues, and are more likely to also be treated with antidepressant drugs
Claro is expected to be available in Spain, UK, Italy and France before the end of the year, and will be made available as part of Almirall’s psoriasis patient support programme.
Happify’s main app – which provides some content for free and can be unlocked completely with a monthly subscription – has more than half a million downloads on Google’s Play store and is also available on Apple devices and PCs.
Last year, the New York-based digital health specialist announced the launch of Kopa for Psoriasis, one of a series of planned management platforms intended to provide support and a community for people with chronic conditions..." Lire la suite